Compugen 관리
관리 기준 확인 3/4
Compugen CEO는 Anat Cohen-Dayag, Jun2009 에 임명되었습니다 의 임기는 15.42 년입니다. 총 연간 보상은 $ 1.46M, 32.7% 로 구성됩니다. 32.7% 급여 및 67.3% 보너스(회사 주식 및 옵션 포함). 는 $ 80.25K 가치에 해당하는 회사 주식의 0.063% 직접 소유합니다. 80.25K. 경영진과 이사회의 평균 재임 기간은 각각 5 년과 7.4 년입니다.
주요 정보
Anat Cohen-Dayag
최고 경영자
US$1.5m
총 보상
| CEO 급여 비율 | 32.7% |
| CEO 임기 | 15.4yrs |
| CEO 소유권 | 0.06% |
| 경영진 평균 재임 기간 | 5yrs |
| 이사회 평균 재임 기간 | 7.4yrs |
최근 관리 업데이트
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$479k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$479k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$498k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$453k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$941k | US$395k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$854k | US$391k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$740k | US$392k | -US$37m |
보상 대 시장: Anat 의 총 보상 ($USD 1.46M )은 US 시장( $USD 652.28K ).
보상과 수익: Anat 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Anat Cohen-Dayag (57 yo)
15.4yrs
테뉴어
US$1,464,448
보상
Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 15.4yrs | US$1.46m | 0.063% $ 80.3k | |
| Chief Scientific Officer | 4.7yrs | US$540.64k | 데이터 없음 | |
| Senior Vice President of Technology Innovation | 6.8yrs | US$532.26k | 데이터 없음 | |
| Vice President of Preclinical Development | 3.6yrs | US$570.40k | 데이터 없음 | |
| Chief Financial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| General Counsel & Corporate Secretary | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resources | 17.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Senior Advisor of Data and Informatics Solutions | 5yrs | 데이터 없음 | 데이터 없음 | |
| Vice President Research and Discovery | no data | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 |
5.0yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: CGEN 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 10.8yrs | US$1.46m | 0.063% $ 80.3k | |
| Member of Scientific Advisory Board | 4.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.4yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 11.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Chairman of the Board | 7.1yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.4yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Scientific Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 11.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 11.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 7.7yrs | 데이터 없음 | 데이터 없음 |
7.4yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 이사회: CGEN 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.